|Videos|December 16, 2021
Biggest FDA News for Multiple Myeloma in 2021
Author(s)Nina Shah, MD
Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.
Advertisement
Episodes in this series
Nina Shah, MD: The biggest FDA news that we got this year was the approval of ide-cel [idecabtagene vicleucel; Abecma]. The reason it’s a big deal for us is that it now changes how we think about our lines 1, 2, 3, and 4, approaching a patient with multiple myeloma, and it allowed us to start getting our hands wet with how to use this and the logistics of that. It’s going to change how we, for example, have apheresis spots in our clinics or what kind of referral patterns we have in the community. It was nice to get that approval to start the ball rolling to hopefully bring this therapy to more patients.
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
4
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
5